CDK4/6-Inhibitors Inclusion in the Treatment of metastatic Hormone Receptor-positive, HER2-negative Breast Cancer

被引：0
|
作者：
Forstmeyer, D. [1 ]
机构：
[1] Univ Klinikum Leipzig, Univ Krebszentrum Leipzig UCCL, Liebigstr 20, D-04103 Leipzig, Germany
来源：
ONKOLOGE | 2016年 / 22卷 / 07期
关键词：
PALBOCICLIB;
D O I：
10.1007/s00761-016-0055-z
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：507 / 508
页数：2
相关论文
共 50 条
  • [31] The impact of vitamin D levels on the progression-free survival of women with hormone receptor-positive, HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors
    Aranda-Gutierrez, Alejandro
    Meraz-Brenez, Andres
    Gonzalez-Sanchez, Hector Raul
    Verduzco-Aguirre, Haydee Cristina
    Martinez-Cannon, Bertha Alejandra
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [32] Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor-positive, HER2-negative Breast Cancer and Emerging Therapeutic Opportunities
    Lloyd, Maxwell R.
    Spring, Laura M.
    Bardia, Aditya
    Wander, Seth A.
    CLINICAL CANCER RESEARCH, 2022, 28 (05) : 821 - 830
  • [33] Immunologic features and association with prognosis in hormone receptor positive/HER2-negative (HR+/HER2) metastatic breast cancer (MBC) treated with chemotherapy (CT) or CDK4/6-inhibitors (CDK4/6i) + endocrine therapy (ET)
    Schettini, Francesco
    Palleschi, Michela
    Mannozzi, Francesca
    Braso-Maristany, Fara
    Cecconetto, Lorenzo
    Galvan, Patricia
    Mariotti, Marita
    Ferrari, Alessia
    Scarpi, Emanuela
    Miserocchi, Anna
    Nanni, Oriana
    Sanfeliu, Esther
    Prat, Aleix
    Rocca, Andrea
    De Giorgi, Ugo
    CANCER RESEARCH, 2024, 84 (09)
  • [34] CDK4/6-Inhibitoren Einzug in die Therapie des metastasierten Hormonrezeptor-positiven, HER2-negativen MammakarzinomsCDK4/6 inhibitors Inclusion in treatment of metastatic hormone receptor-positive HER2-negative breast cancer
    D. Forstmeyer
    Der Onkologe, 2016, 22 (7): : 507 - 508
  • [35] Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor-Positive (HR+)/HER2-Negative Metastatic Breast Cancer
    Davis, Andrew A.
    Luo, Jingqin
    Zheng, Tiantian
    Dai, Chao
    Dong, Xiaoxi
    Tan, Lu
    Suresh, Rama
    Ademuyiwa, Foluso O.
    Rigden, Caron
    Rearden, Timothy P.
    Clifton, Katherine
    Weilbaecher, Katherine
    Frith, Ashley
    Tandra, Pavan K.
    Summa, Tracy
    Haas, Brittney
    Thomas, Shana
    Hernandez-Aya, Leonel F.
    Peterson, Lindsay L.
    Wang, Xiaohong
    Luo, Shujun J.
    Zhou, Kemin
    Du, Pan
    Jia, Shidong
    King, Bonnie L.
    Krishnamurthy, Jairam
    Ma, Cynthia X.
    CLINICAL CANCER RESEARCH, 2023, 29 (09) : 1719 - 1729
  • [36] Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors
    Zattarin, Emma
    Mariani, Luigi
    Menichetti, Alice
    Leporati, Rita
    Provenzano, Leonardo
    Ligorio, Francesca
    Fuca, Giovanni
    Lobefaro, Riccardo
    Lalli, Luca
    Vingiani, Andrea
    Nichetti, Federico
    Griguolo, Gaia
    Sirico, Marianna
    Bernocchi, Ottavia
    Marra, Antonio
    Corti, Chiara
    Zagami, Paola
    Agostinetto, Elisa
    Jacobs, Flavia
    Di Mauro, Pierluigi
    Presti, Daniele
    Sposetti, Caterina
    Giorgi, Carlo Alberto
    Guarneri, Valentina
    Pedersini, Rebecca
    Losurdo, Agnese
    Generali, Daniele
    Curigliano, Giuseppe
    Pruneri, Giancarlo
    de Braud, Filippo
    Dieci, Maria Vittoria
    Vernieri, Claudio
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [37] Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors
    Zattarin, Emma
    Mariani, Luigi
    Menichetti, Alice
    Leporati, Rita
    Provenzano, Leonardo
    Ligorio, Francesca
    Fuca, Giovanni
    Lobefaro, Riccardo
    Lalli, Luca
    Vingiani, Andrea
    Nichetti, Federico
    Griguolo, Gaia
    Sirico, Marianna
    Bernocchi, Ottavia
    Marra, Antonio
    Corti, Chiara
    Zagami, Paola
    Agostinetto, Elisa
    Jacobs, Flavia
    Di Mauro, Pierluigi
    Presti, Daniele
    Sposetti, Caterina
    Giorgi, Carlo Alberto
    Guarneri, Valentina
    Pedersini, Rebecca
    Losurdo, Agnese
    Generali, Daniele
    Curigliano, Giuseppe
    Pruneri, Giancarlo
    de Braud, Filippo
    Dieci, Maria Vittoria
    Vernieri, Claudio
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [38] TREATMENT OF PREMENOPAUSAL PATIENTS WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE METASTATIC BREAST CANCER WITH AN CDK4/6 INHIBITOR COMBINED WITH ENDOCRINE AGENTS: A REAL-WORLD EXPERIENCE
    Kurbacher, Christian Martin
    Fischer, Lotta Ada
    Heinrich, Georg
    Warm, Mathias
    Schott, Alexander
    Kurbacher, A. Tabea
    Kurbacher, Jutta Anna
    Rudlowski, Christian
    BREAST, 2019, 48 : S55 - S56
  • [39] Hormone receptor-positive, HER2-negative metastatic breast cancer: redrawing the lines
    Matutino, A.
    Joy, A. A.
    Brezden-Masley, C.
    Chia, S.
    Verma, S.
    CURRENT ONCOLOGY, 2018, 25 : S131 - S141
  • [40] Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer
    Lin, Mingxi
    Chen, Yang
    Jin, Yizi
    Hu, Xichun
    Zhang, Jian
    JOURNAL OF CANCER, 2020, 11 (24): : 7127 - 7136
12345